Supported by

TAVI (Transcatheter aortic valve implantation)

Here you will find all the latest content on transcatheter aortic valve implantations (TAVI) published on this website. Results are listed in chronological order. TAVI, now an established, valid treatment for patients presenting with symptomatic severe aortic stenosis, has proven to be superior to medical treatment for inoperable patients whilst being a valid alternative to surgery in select, high-risk patients. This topic covers the newest devices and emerging data in TAVI as well as information on tools, devices and techniques such as vascular access; the role of adjunctive pharmacotherapy; imaging techniques such as echocardiography, understanding bleeding risks or patient selection. Find out more…

Filtered By

594 results

EuroIntervention Journal: Leaflet thrombosis after TAVI and valve-in-valve procedures

25 Sep 2017

Consult the study on "Effect of reduced cardiac output on blood stasis on transcatheter aortic valve leaflets: implications for valve thrombosis" by K. Vahidkah et al.

How should I treat a small, failing surgical bioprosthesis in a high surgical risk patient?

14 Sep 2017

A 77-year-old female who underwent surgical aortic valve replacement with a 21mm Mosaic bioprosthesis 13 years prior presented with worsening dyspnea on exertion. The patient was considered high surgical risk, so surgical valve replacement as well as valve-in-valve transcatheter aortic valve implantation were discussed as a treatment options.


Valve in Valve: Breaking New Ground…

10 Sep 2017

Herein, we present 3 important studies concerning the use of transcatheter aortic valve implantation (TAVI) within small degenerated surgical bioprosthetic valves. In such cases, left main coronary occlusion and high post-implant gradients are not infrequently encountered, increasing mortality and curtailing symptomatic improvement.

New ESC/EACTS Guidelines for the management of Valvular Heart Disease (VHD)

31 Aug 2017

The new joint ESC/EACTS guidelines for the management of valvular heart disease have been hotly anticipated, with extended indications for transcutaneous aortic valve implantation (TAVI) widely tipped to be the star of the show. In comparison to 2012, where data from two randomized control trials assessing TAVI were available, outcome data from nearly six thousand patients across six randomized trials were available to the 2017 guideline writing committee. Therefore, the major challenge for this guideline was to assimilate this data and make it applicable in realworld clinical practice. In that regard, this new document has evolved beyond simple ‘guidance’ and now introduces new ‘concepts of care’ for patients with valvular heart disease.

Christopher Cook


Christopher Cook

Sequential percutaneous approach for valvular disease

18 May 2017 – From EuroPCR 2017

Is survival and cause of death really different after TAVI? Surprising insights from Denmark

Under the leadership of Lars Søndergrad, the Rigs Hospital in Denmark is publishing a paper entitled “Survival and cause of death after transcatheter aortic valve replacement as compared to an age- and sex-matched background population”. As a small country, Danish physicians and healthcare delivery are extremely well organised, with complex treatments centralised in a few hospitals with great expertise, thus data collection is greatly enhanced.

SOURCE 3 post-approval registry—One-year outcomes in 1,946 TAVI patients with a 3rd generation balloon transcatheter heart valve

Speaker: O. Wendler

At 1 year, patients treated via the transfemoral access route had a high survival rate (88.2 percent) and a low disabling stroke rate (1.1 percent).Patients experienced a low rate (2.7 percent) of moderate paravalvular leak and no severe paravalvular leak.

Commemorating the 15-year anniversary of TAVI: insights into the early stages of development, from concept to human application, and perspectives

A. Cribier. shares his experience of cardiac catheterisation in the early 1970s and follow the fascinating evolution of the technology over the past 40 years.

Authors :

Alain Cribier

Explore the SOURCE 3 Registry: Real-World Evidence With the Edwards SAPIEN 3 Transcatheter Heart Valve

At EuroPCR 2017, new one-year data from a post-approval study of the Edwards SAPIEN 3 valve demonstrated positive patient outcomes, including high survival rates, low rates of stroke, and low rates of paravalvular leak.

The majority of patients in the SOURCE 3 Registry were treated via transfemoral access, and more than half were treated under conscious sedation. SOURCE 3 patients were enrolled at 80 centres across 10 countries between July 2014 and October 2015, and will continue to be followed for five years post-TAVI.

How should I treat a patient with severe aortic valve stenosis with highly impaired left ventricular function and concomitant coronary heart disease?

07 Aug 2017

A complex and challenging case of a 71 year-old male with severe bicuspid aortic stenosis (with moderate regurgitation) and concomitant coronary artery disease and severe left ventricle dysfunction...